^
    16h
    Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=225, Recruiting, University Hospital Tuebingen | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    23h
    POLARIS: Adjuvant Intensification for LAR (clinicaltrials.gov)
    P3, N=904, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus
    1d
    Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    2d
    Onvansertib + Paclitaxel In TNBC (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Antonio Giordano, MD | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • onvansertib (PCM-075)
    3d
    ESPRESSOBREAST: Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers (clinicaltrials.gov)
    P=N/A, N=1050, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 positive + HER-2 overexpression
    3d
    Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=416, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    4d
    Tumor-Intrinsic PD-1 Regulatory Network Drives Lapatinib Resistance in HER2⁺ Breast Cancer: An Integrative Bioinformatics Analysis. (PubMed, Asian Pac J Cancer Prev)
    The findings revealed that the PLR regulatory network is associated with HER2⁺/ER-/PR- lapatinib resistance through multiple mechanisms, including interferon signaling silencing, T cell exhaustion, and the fostering of an immunosuppressive niche. These insights pave the way for interventions aimed at overcoming lapatinib resistance in HER2⁺ breast cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • B2M (Beta-2-microglobulin) • ITGB2 (Integrin Subunit Beta 2)
    |
    lapatinib
    4d
    Overall Survival in Breast Cancer Patients: Analysis of a 27-Year Historical Cohort. (PubMed, Asian Pac J Cancer Prev)
    During the study period, the overall survival rate in this cohort of women with breast cancer was 83.1% at five years and 65.5% at ten years. Different clinical, biological and tumor-related factors significantly affected prognosis in this population.
    Retrospective data • Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    7d
    Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (clinicaltrials.gov)
    P3, N=1978, Not yet recruiting, National Cancer Institute (NCI)
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane
    7d
    SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PD-L1 negative • ER negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • tiragolumab (RG6058)
    8d
    NOHA as a key biomarker to link NOS2 activity to immune checkpoint and cytokine signaling in ER-negative breast cancer. (PubMed, Biochem Biophys Rep)
    The pronounced effects in AA-derived ER- spheroids align with known disparities in tumor aggressiveness and suggest future NOHA clinical utility potential in racially diverse populations. Further in vivo validation is warranted to support and confirm such clinical translation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • NOS2 (Nitric Oxide Synthase 2)
    |
    ER negative
    12d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P3 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354